Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 06:51 am EST
Share
Leap Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 11.14 million compared to USD 7.06 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.09 a year ago.
For the nine months, net loss was USD 29.8 million compared to USD 20.8 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.58 a year ago.
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.